Spots Global Cancer Trial Database for Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Official Title: Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer: the CHASIT Study
Study ID: NCT05600127
Conditions
Interventions
Study Description
Brief Summary: Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
Detailed Description: Patients with locally advanced or clinically node positive urothelial carcinoma of the bladder, ureter or urethra (cT4NxM0 or cTxN1-N3M0) with at least stable disease after treatment with 3-4 cycles of platinum-based chemotherapy, will be treated with 3 cycles of avelumab (anti-PD-L1). If there are no signs of disease progression after avelumab treatment, radical surgery of the primary tumor and a pelvic lymph node dissection will follow.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Amphia ziekenhuis, Breda, Brabant, Netherlands
Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands
Radboud UMC, Nijmegen, Gelderland, Netherlands
Erasmus MC, Rotterdam, Zuid Holland, Netherlands
Contact Details
Name: J L Boormans, MD PhD
Affiliation: Erasmus Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
